Subtype
Brain Neoplasm
CI-CAN-00002030Explore in graph →
Non-malignant511 active trials34 evidence items
Loading cancer entity…
Subtype
CI-CAN-00002030Explore in graph →
Clinical trials
2,117 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04085887 | Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures | recruiting | Phase 1 / Phase 2 | 12 | Stanford UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05685004 | Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | active not recruiting | Phase 2 / Phase 3 | 120 | TVAX BiomedicalINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | active not recruiting | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | recruiting | Phase 2 | 162 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04684368 | A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | recruiting | Phase 2 | 160 | Children's Oncology GroupNETWORK | 4 | Sep 23, 2026 | clinicaltrials |
| NCT02153957 | Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors | completed | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02792582 | A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection | active not recruiting | Phase 2 | 160 | St. Jude Children's Research HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03197506 | Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma | active not recruiting | Phase 2 | 52 | Mayo ClinicOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03210714 | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT07248228 | Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial) | recruiting | Phase 2 | 90 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07470606 | Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain(MemoryRT) | recruiting | Phase 2 | 108 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03698994 | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Sep 21, 2026 | clinicaltrials |
| NCT05050929 | RAPid SimPLE Targeted Radiation Treatment for Brain Metastases(RAPPLE) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06804655 | Pharmacoscopy for Patients With Refractory Primary Brain Tumors(EViDENCE-BT) | recruiting | Phase 2 | 40 | University of ZurichOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06838676 | ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | recruiting | Phase 2 | 60 | Nationwide Children's HospitalOTHER | 5 | Sep 21, 2026 | clinicaltrials |
| NCT03158064 | Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | active not recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03508752 | Neurocognitive Decline in Patients With Brain Metastases | active not recruiting | Phase 1 / Phase 2 | 80 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05048212 | A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases | recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07053033 | Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM) | recruiting | Phase 2 | 155 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07227610 | Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) | recruiting | Phase 2 | 54 | Medical University of South CarolinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03818386 | Radiotherapy of Multiple Brain Metastases Using AGuIX®(NANORAD2) | completed | Phase 2 | 106 | University Hospital, GrenobleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05535166 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | recruiting | Phase 2 | 130 | St. Jude Children's Research HospitalOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02747303 | Frameless Stereotactic Radiosurgery for Intact Brain Metastases | recruiting | Phase 2 | 166 | University of ChicagoOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II) | suspended | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05052957 | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)(hSTAR GBM) | recruiting | Phase 2 | 16 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT02847559 | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | completed | Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer(ELECTRA) | recruiting | Phase 1 / Phase 2 | 73 | Stemline Therapeutics, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT06315010 | Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis(REPOSE) | recruiting | Phase 2 | 20 | MedSIROTHER | 3 | Sep 9, 2026 | clinicaltrials |
| NCT06329570 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 / Phase 2 | 10 | NaviFUS CorporationINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07644312 | Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG | not yet recruiting | Phase 2 | 12 | Nationwide Children's HospitalOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05588141 | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06701812 | Digoxin Medulloblastoma Study | recruiting | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05948813 | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | recruiting | Phase 2 | 420 | TYK Medicines, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06368817 | A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | recruiting | Phase 2 | 240 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05096481 | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | recruiting | Phase 2 | 120 | Nationwide Children's HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT00918320 | Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours(TOTEM2) | completed | Phase 2 | 129 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT01419067 | A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection | active not recruiting | Phase 2 | 112 | St. Jude Children's Research HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT00407433 | Clinical Studies of Gemcitabine-Oxaliplatin | completed | Phase 2 | 156 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT01326104 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH) | completed | Phase 2 | 26 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
Data updated 2 hours agoSource updated Sep 29, 2026source: clinicaltrials